1. Home
  2. PROK

PROK

ProKidney Corp.

Logo ProKidney Corp.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-17-2024 12:31pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.

Founded: 2015 Country:
United States
United States
Employees: N/A City: WINSTON-SALEM
Market Cap: 91.8M IPO Year: N/A
Target Price: $7.00 AVG Volume (30 days): 575.4K
Analyst Decision: Buy Number of Analysts: 3
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.57 EPS Growth: N/A
52 Week Low/High: $1.12 - $13.51 Next Earning Date: 05-09-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: